X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Cell Line Name

*NOTICE: Multiple vendors found, please select your record:

RRID:CVCL_2142 RRID Copied  
PDF Report How to cite
(DSMZ Cat# ACC-488, RRID:CVCL_2142)
Copy Citation Copied
Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2142

Proper Citation: (DSMZ Cat# ACC-488, RRID:CVCL_2142)

Description: Cell line NK-92 is a Cancer cell line with a species of origin Homo sapiens

Sex: Male

Disease: Natural killer cell lymphoblastic leukemia/lymphoma

Defining Citation: PMID:8152260, PMID:9118301, PMID:9573023, PMID:10365666, PMID:10803505, PMID:11454312, PMID:12850795, PMID:18424763, PMID:19194464, PMID:20454443, PMID:21052088, PMID:21570725, PMID:25586472, PMID:26559813, PMID:30054012, PMID:31126350, PMID:31160637, PMID:34349345

Comments: Derived from sampling site: Peripheral blood. Cell type=Natural killer cell., Caution: This cell line is exclusively owned and controlled by NantKwest, Inc. NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support.., Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing.., Omics: Transcriptome analysis., Omics: Deep RNAseq analysis., Omics: Deep exome analysis., Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV)., Doubling time: 35.6 +- 6.1 hours (PubMed=31126350); ~40-50 hours (DSMZ)., Characteristics: Does not express FCGR3A/CD16., Characteristics: IL2 dependent., Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing. Also being developed for cellular adoptive immunotherapy for cancers and viral infections., Part of: LL-100 blood cancer cell line panel., Group: Patented cell line., Discontinued: BCRC; 60414; true.

Category: Cancer cell line

Expand All
Usage and Citation Metrics
We apologize, the data for 2022 is currently unavailable for most resources. We are aware of the issue and are working to resolve it.

We found {{ ctrl2.mentions.total_count }} mentions in open access literature.

We have not found any literature mentions for this resource.

We are searching literature mentions for this resource.

View full usage report

Most recent articles:

{{ mention._source.dc.creators[0].familyName }} {{ mention._source.dc.creators[0].initials }}, et al. ({{ mention._source.dc.publicationYear }}) {{ mention._source.dc.title }} {{ mention._source.dc.publishers[0].name }}, {{ mention._source.dc.publishers[0].volume }}({{ mention._source.dc.publishers[0].issue }}), {{ mention._source.dc.publishers[0].pagination }}. (PMID:{{ mention._id.replace('PMID:', '') }})

Checkfor all resource mentions.

Collaborator Network

A list of researchers who have used the resource and an author search tool

Find mentions based on location


{{ ctrl2.mentions.errors.location }}

A list of researchers who have used the resource and an author search tool. This is available for resources that have literature mentions.

Ratings and Alerts

No rating or validation information has been found for NK-92.

Discontinued
Discontinued: ATCC; PTA-6670

Discontinued
Discontinued: BCRC; 60414

View More at BIOMED RESOURCE WATCH

Data and Source Information

Source: Cellosaurus